Clinical Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
College of Medicine, Qatar University, Doha, Qatar.
Eur J Clin Invest. 2021 Sep;51(9):e13645. doi: 10.1111/eci.13645. Epub 2021 Jul 18.
Colchicine was recently repurposed for the management of coronavirus disease 2019 (COVID-19). This rapid review and meta-analysis aimed to assess colchicine's impact on mortality outcomes in COVID-19 patients.
We systematically searched PubMed, EMBASE, Google Scholar since their inception till 25/03/2021 for observational or controlled studies that reported mortality as an outcome. The mortality odd ratios were generated with their corresponding 95% confidence intervals utilizing the random-effects model.
Nine studies comprising 5522 patients met our inclusion criteria. Our meta-analysis revealed significantly lower mortality in the colchicine group (OR 0.35, 95% CI 0.25-0.48, I2 0%) compared with controls. A subgroup analysis limited to hospitalized patients (OR 0.35, 95% CI 0.25-0.50, I2 0%) revealed similarly lower mortality in the colchicine group.
This meta-analysis suggests a mortality benefit with colchicine when used in the treatment of COVID-19 patients. The majority of included studies were observational; thus, the findings of this review need to be further supported by the results of ongoing trials.
秋水仙碱最近被重新用于治疗 2019 年冠状病毒病（COVID-19）。本快速综述和荟萃分析旨在评估秋水仙碱对 COVID-19 患者死亡率结局的影响。
我们系统地检索了 PubMed、EMBASE 和 Google Scholar，检索时间从建库至 2021 年 3 月 25 日，以查找报告死亡率结局的观察性或对照研究。利用随机效应模型生成死亡率比值比及其相应的 95%置信区间。
共有 9 项研究纳入了 5522 例患者，符合我们的纳入标准。荟萃分析显示，与对照组相比，秋水仙碱组的死亡率显著降低（比值比 0.35，95%置信区间 0.25-0.48，I2=0%）。对仅限于住院患者的亚组分析（比值比 0.35，95%置信区间 0.25-0.50，I2=0%）显示，秋水仙碱组的死亡率也显著降低。
本荟萃分析表明，秋水仙碱治疗 COVID-19 患者可降低死亡率。纳入的大多数研究为观察性研究；因此，本综述的结果需要正在进行的试验的结果进一步证实。
